Biotech Values

[vinmantoo]

NIH wants_to_study longer treatment_course for Paxlovid:

That could be problematic for the high risk groups that are the prime target for the PFE regimen given it increases the half-life and increases levels of other drugs patients tested.

The Paxlovid treatment course under the existing EUA is 5 days. However, this is not because 5 days is necessarily optimal, but rather because 5 days is how long the treatment was in PFE’s phase-3 clinical trial.

I wonder if ENTA will be adding a longer regimen for one of its EDP-235 phase 2/3 trials?